PMID- 25036574
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141013
LR  - 20231110
IS  - 1598-2998 (Print)
IS  - 2005-9256 (Electronic)
IS  - 1598-2998 (Linking)
VI  - 46
IP  - 4
DP  - 2014 Oct
TI  - Analysis of biologically equivalent dose of stereotactic body radiotherapy for 
      primary and metastatic lung tumors.
PG  - 403-10
LID - 10.4143/crt.2013.168 [doi]
AB  - PURPOSE: The purpose of this study was to determine the optimal biologically 
      equivalent dose (BED) for stereotactic body radiotherapy (SBRT) by comparing 
      local control rates in proportion to various total doses and fractionation 
      schedules. MATERIALS AND METHODS: Thirty-four patients with early non-small-cell 
      lung cancer and a single metastatic lung tumor were included in this study. 
      Differences in local control rates were evaluated according to gender, primary 
      tumor site, response, tumor size, and BED. For comparison of BEDs, the prescribed 
      dose for SBRT was stratified according to three groups: high (BED > 146 Gy), 
      medium to high (BED, 106 to 146 Gy), and low to medium (BED < 106 Gy). RESULTS: 
      For all patients, the overall local control rate was 85.3% at two years after 
      treatment. Five local recurrences were observed, and, notably, all of them were 
      observed in the low to medium BED group. Significantly higher local control rates 
      were observed for patients with a complete response than for those with a partial 
      response or stable disease (p < 0.001). Twenty-six patients with a tumor size of 
      < 3 cm showed no dose-response relationship in the low to medium, medium to high, 
      and high BED groups, whereas eight patients with a tumor size of >/= 3 cm showed a 
      significant dose-response relationship. The observed 2-year local recurrence-free 
      survival rates in patients with a tumor size of < 3 cm and in those with a tumor 
      size of >/= 3 cm were 96.2% and 50.0%, respectively, which were significantly 
      different (p=0.007). CONCLUSION: BED > 100 Gy is required in order to achieve a > 
      85% local control rate regardless of tumor size. The optimal dose for small 
      tumors of < 3 cm appears to be within a range below 150 Gy BED. Escalation of BED 
      to high levels (> 150 Gy) may be required for patients with a tumor size larger 
      than 3 cm.
FAU - Park, Sungkwang
AU  - Park S
AD  - Department of Radiation Oncology, Inje University Busan Paik Hospital, Inje 
      University College of Medicine, Busan, Korea.
FAU - Urm, Sanghwa
AU  - Urm S
AD  - Department of Preventive Medicine, Inje University College of Medicine, Busan, 
      Korea.
FAU - Cho, Heunglae
AU  - Cho H
AD  - Department of Radiation Oncology, Inje University Busan Paik Hospital, Inje 
      University College of Medicine, Busan, Korea.
LA  - eng
PT  - Journal Article
DEP - 20140717
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment
JID - 101155137
PMC - PMC4206062
OTO - NOTNLM
OT  - Biologically effective dose
OT  - Lung
OT  - Neoplasm metastasis
OT  - Stereotactic body radiotherapy
COIS- Conflict of interest relevant to this article was not reported.
EDAT- 2014/07/19 06:00
MHDA- 2014/07/19 06:01
PMCR- 2014/10/01
CRDT- 2014/07/19 06:00
PHST- 2013/09/03 00:00 [received]
PHST- 2013/11/03 00:00 [accepted]
PHST- 2014/07/19 06:00 [entrez]
PHST- 2014/07/19 06:00 [pubmed]
PHST- 2014/07/19 06:01 [medline]
PHST- 2014/10/01 00:00 [pmc-release]
AID - crt.2013.168 [pii]
AID - crt-2013-168 [pii]
AID - 10.4143/crt.2013.168 [doi]
PST - ppublish
SO  - Cancer Res Treat. 2014 Oct;46(4):403-10. doi: 10.4143/crt.2013.168. Epub 2014 Jul 
      17.